PATHOPHYSIOLOGY OF PSYCHIATRIC DISORDERS GROUP
Research conducted by the Pathophysiology of Psychiatric Disorders team aims to answer two major questions : the Etiology of Depression, and the function of Dopamine in the pathophysiology of schizophrenia.
Our fundamental and preclinical studies have identified new mechanisms contributing to individual vulnerability or resistance (resiliency) to depression and underlying the action of antidepressants. Ongoing projects aim to further elucidate the role of these novel systems in plasticity-related processes within the neural circuitry in normal and pathological conditions. We will also investigate whether certain of these systems constitute valid biomarkers in humans, to assess the efficacy of antidepressant therapies, and we are currently developing selective approaches to manipulate their activity in order to improve antidepressant efficacy.
Research topics
Theme 1: Etiology of depression
– Neural networks in vulnerability and resiliance to depression
Theme 2: Dopamine hypothesis and pathophysiology of schizophrenia
– Dopamine transporter (DAT) interactome and proteome
characterizing DA dynamics in cortical areas
– Functional diversity of dopaminoceptive Medium Spiny Neurons
Functional diversity of dopaminoceptive Medium Spiny Neurons
TEAM MEMBERS
Permanent researchers
Visiting scientists
Support staff
Members
Post docs and PhD students
︾ PUBLICATIONS ︾
Recent Publications
Articles
- Orrico-Sanchez A, Chausset-Boissarie L, Alves de Sousa R, Coutens B, Rezai Amin S, Vialou V, Louis F, Hessani A, Dansette PM, Zornoza T, Gruszczynski C, Giros B, Guiard BP, Acher F, Pietrancosta N, Gautron S. Antidepressant efficacy of a selective organic cation transporter blocker in a mouse model of depression. Mol Psychiatry, 2020, 25 (6), pp.1245-1259.
- Poirel O, Mamer LE, Herman MA, Arnulf-Kempcke M, Kervern M, Potier B, Miot S, Wang J, Favre-Besse FC, Brabet I, Laras Y, Bertrand HO, Acher F, Pin JP, Puel JL, Giros B, Epelbaum J, Rosenmund C, Dutar P, Daumas S, El Mestikawy S, Pietrancosta N. LSP5-2157 a new inhibitor of vesicular glutamate transporters. Neuropharmacology, 2020, 164, pp.107902.
- Laboute T, Gandía J, Pellissier LP, Corde Y, Rebeillard F, Gallo M, Gauthier C, Léauté A, Diaz J, Poupon A, Kieffer BL, Le Merrer J, Becker JA. The orphan receptor GPR88 blunts the signaling of opioid receptors and multiple striatal GPCRs. Elife, 2020, 9.
- Diaz J, Gérard X, Emerit MB, Areias J, Geny D, Dégardin J, Simonutti M, Guerquin MJ, Collin T, Viollet C, Billard JM, Métin C, Hubert L, Larti F, Kahrizi K, Jobling R, Agolini E, Shaheen R, Zigler A, Rouiller-Fabre V, Rozet JM, Picaud S, Novelli A, Alameer S, Najmabadi H, Cohn R, Munnich A, Barth M, Lugli L, Alkuraya FS, Blaser S, Gashlan M, Besmond C, Darmon M, Masson J. YIF1B mutations cause a post-natal neurodevelopmental syndrome associated with Golgi and primary cilium alterations. Brain, 2020, 143 (10), pp.2911-2928.
- Hernandez G, Mahmoudi S, Cyr M, Diaz J, Blanchet PJ, Lévesque D. Tardive dyskinesia is associated with altered putamen Akt/GSK-3β signaling in nonhuman primates. Mov Disord, 2019, 34 (5), pp.717-726.